Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

Cited In for PubMed (Select 8841192)

1.

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.

Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D, Tonin PN.

J Ovarian Res. 2015 Mar 27;8(1):1. doi: 10.1186/s13048-015-0124-8.

2.

Genetic counseling content: How does it impact health behavior?

Kelly KM, Ellington L, Schoenberg N, Jackson T, Dickinson S, Porter K, Leventhal H, Andrykowski M.

J Behav Med. 2014 Dec 23. [Epub ahead of print]

PMID:
25533642
3.

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.

Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S.

Br J Cancer. 2014 Sep 9;111(6):1132-8. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.

PMID:
25072261
4.

Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Couch FJ, Nathanson KL, Offit K.

Science. 2014 Mar 28;343(6178):1466-70. doi: 10.1126/science.1251827.

5.

Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma.

Reznik R, Hendifar AE, Tuli R.

Front Physiol. 2014 Mar 3;5:87. doi: 10.3389/fphys.2014.00087. eCollection 2014. Review.

6.

The population genetics of the Jewish people.

Ostrer H, Skorecki K.

Hum Genet. 2013 Feb;132(2):119-27. doi: 10.1007/s00439-012-1235-6. Epub 2012 Oct 10. Review.

7.

The role of BRCA1 and BRCA2 in prostate cancer.

Castro E, Eeles R.

Asian J Androl. 2012 May;14(3):409-14. doi: 10.1038/aja.2011.150. Epub 2012 Apr 23. Review.

8.

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.

J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.

9.

Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.

Metcalfe KA, Narod SA.

Open Med. 2007;1(3):e184-90. Epub 2007 Dec 18. No abstract available.

PMID:
21673951
Free PMC Article
10.

Pathology of hereditary breast cancer.

van der Groep P, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Apr;34(2):71-88. doi: 10.1007/s13402-011-0010-3. Epub 2011 Feb 19. Review.

11.

Update on familial pancreatic cancer.

Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP.

Adv Surg. 2010;44:293-311. Review. No abstract available.

12.

African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.

Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L.

Cancer. 2010 Nov 1;116(21):4926-32. doi: 10.1002/cncr.25276.

13.

A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice.

Ferris M, Easton DF, Doherty RJ, Briggs BH, Newman M, Saraf IM, Scambler S, Wagman L, Wyndham MT, Ward A, Eeles RA.

Hered Cancer Clin Pract. 2007 Sep 15;5(3):157-60. doi: 10.1186/1897-4287-5-3-157.

14.

Impact of BRCA mutations on female fertility and offspring sex ratio.

Moslehi R, Singh R, Lessner L, Friedman JM.

Am J Hum Biol. 2010 Mar-Apr;22(2):201-5. doi: 10.1002/ajhb.20978.

15.

A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing.

Zhang L, Kirchhoff T, Yee CJ, Offit K.

J Mol Diagn. 2009 May;11(3):176-81. doi: 10.2353/jmoldx.2009.080137. Epub 2009 Mar 26.

16.

BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.

Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW.

Cancer. 2009 May 15;115(10):2222-33. doi: 10.1002/cncr.24200. Erratum in: Cancer. 2009 Jun 15;115(12):2804.

17.

Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.

Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T.

BMC Cancer. 2009 Feb 18;9:60. doi: 10.1186/1471-2407-9-60.

18.

Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations.

Holt JT, Toole WP, Patel VR, Hwang H, Brown ET.

Cancer Genet Cytogenet. 2008 Oct 15;186(2):85-94. doi: 10.1016/j.cancergencyto.2008.06.013.

19.

The role of the BRCA2 gene in susceptibility to prostate cancer revisited.

Ostrander EA, Udler MS.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1843-8. doi: 10.1158/1055-9965.EPI-08-0556. Review.

20.

Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.

Kuznetsov SG, Liu P, Sharan SK.

Nat Med. 2008 Aug;14(8):875-81. doi: 10.1038/nm.1719. Epub 2008 Jul 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk